Allergic rhinitis

Altamira Therapeutics Continue Bentrio Clinical Trial for Seasonal Allergic Rhinitis in Australia

Retrieved on: 
Montag, Oktober 3, 2022
Terminology, Securities & Exchange Commission of Pakistan, MITES, Hearing loss, Vertigo, GLOBE, OTC, Securities Exchange Act of 1934, NASDAQ, SEC, Risk, Nose, Clinical trial, U.S. Securities and Exchange Commission, Securities Act of 1933, Food, Tinnitus, Therapy, CEO, Virus, SAR, FDA, Nasal mucosa, Annual report, Pollen, Allergen, RNA, Safety, Allergic rhinitis, Cell, Nasal spray, Patient, Person, Interim, Forward-looking statement, US Foods, NASAR, Company, Pharmaceutical industry

The primary endpoint will be the comparison of the reflective Total Nasal Symptom Score (rTNSS) under treatment with Bentrio against control.

Key Points: 
  • The primary endpoint will be the comparison of the reflective Total Nasal Symptom Score (rTNSS) under treatment with Bentrio against control.
  • Interim data from the trial were used in support of the 510(k) clearance of Bentrio by the US Food and Drug Administration (FDA).
  • We are pleased to have the first patient randomized into the continuation of the NASAR trial as the annual pollen season starts in Australia, commented Thomas Meyer, Altamira Therapeutics founder, Chairman and CEO.
  • For more info, visit: https://altamiratherapeutics.com/our-products/bentrio
    Altamira Therapeutics (NASDAQ:CYTO) is dedicated to developing therapeutics that address important unmet medical needs.

Altamira Therapeutics Re-launches Bentrio in Europe for Allergic Rhinitis

Retrieved on: 
Dienstag, September 27, 2022
Securities Exchange Act of 1934, Seawater, Therapy, Risk, U.S. Securities and Exchange Commission, Vertigo, Allergen, COVID-19, Nasal spray, FDA, Virus, MITES, Securities Act of 1933, Pollen, Securities & Exchange Commission of Pakistan, Hearing loss, Company, Tinnitus, Pharmacy, Degenerative disease, Person, Forward-looking statement, Clinical trial, CEO, OTC, Interim, Terminology, Annual report, Allergic rhinitis, NASDAQ, RNA, SEC, Marketing, Pharmaceutical industry, EU

Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that its Bentrio nasal spray will be re-launched in Europe, initially in Germany, beginning in early October of 2022.

Key Points: 
  • Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that its Bentrio nasal spray will be re-launched in Europe, initially in Germany, beginning in early October of 2022.
  • Altamira will market Bentrio for helping to prevent onset and alleviate allergic symptoms caused by airborne allergens such as pollen, house dust mites or animal dander.
  • We look forward to bringing Bentrio back to the market in Europe with a labeling specifically for allergic rhinitis, commented Thomas Meyer, the Companys founder, CEO and Chairman.
  • Altamira Therapeutics (NASDAQ:CYTO) is dedicated to developing therapeutics that address important unmet medical needs.

Altamira Therapeutics Completes Enrollment for COVAMID Trial with Bentrio in Acute COVID-19

Retrieved on: 
Dienstag, September 13, 2022
Securities Exchange Act of 1934, Therapy, Risk, U.S. Securities and Exchange Commission, Safety, Vertigo, Allergen, COVID-19, Nasal spray, Virus, Securities Act of 1933, Severe acute respiratory syndrome coronavirus 2, Securities & Exchange Commission of Pakistan, Hearing loss, Company, Population, Tinnitus, Degenerative disease, Nose, Person, Forward-looking statement, Patient, Infection, OTC, Viral load, Terminology, Cell, Annual report, Allergic rhinitis, NASDAQ, RNA, Nasal mucosa, SEC, Pharmaceutical industry, Vaccine

In the COVAMID trial, the COVID-19 patients are randomized at a 2:1:1 ratio to receive for 10 days either Bentrio, a placebo (Bentrio minus its key mineral component), or no treatment, followed by a 10-day observation phase.

Key Points: 
  • In the COVAMID trial, the COVID-19 patients are randomized at a 2:1:1 ratio to receive for 10 days either Bentrio, a placebo (Bentrio minus its key mineral component), or no treatment, followed by a 10-day observation phase.
  • Altamira expects to announce top-line data from the COVAMID trial during the fourth quarter of 2022.
  • For more info, visit: https://altamiratherapeutics.com/our-products/bentrio
    Altamira Therapeutics (NASDAQ:CYTO) is dedicated to developing therapeutics that address important unmet medical needs.
  • All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira Therapeutics or to persons acting on behalf of Altamira Therapeutics are expressly qualified in their entirety by reference to these risks and uncertainties.

Allermi Launches First and Only Customized, Multi-Ingredient Nasal Spray to Offer Relief to Millions of Allergy Sufferers

Retrieved on: 
Donnerstag, September 8, 2022
Nose, Rhinitis, Harvard University, CEO, Conditional sentence, Stanford University, Itchy, Nasal spray, SAN, Allergic rhinitis, Cough, Patient, Pharmaceutical industry, Health insurance

Unlike typical allergy treatments, Allermi nasal sprays contain multiple active ingredients, customized for each patient's symptoms and severity.

Key Points: 
  • Unlike typical allergy treatments, Allermi nasal sprays contain multiple active ingredients, customized for each patient's symptoms and severity.
  • Nasal allergy, also known as hay fever or allergic rhinitis, is a chronic disease affecting 1 in 3 people.
  • "Despite an abundance of over-the-counter treatments and billions of dollars spent per year, nearly 70% of allergy sufferers are dissatisfied with available allergy medications," said Shani Bocian, CEO and Allermi Co-Founder.
  • "This results in suboptimal relief for millions of allergy sufferers who continue to experience symptoms despite taking medications."

Perennial Allergic Rhinitis Epidemiology and Market Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Donnerstag, September 8, 2022
Health, Pharmaceutical, Allergic rhinitis, Algorithm, Disease, Report, Therapy, Epidemiology, Research, Acquisition, Rhinitis, Diagnosis, Awareness, Cochineal, Health insurance, Medical device, Pharmaceutical industry

The "Perennial Allergic Rhinitis - Market Insight, Epidemiology and Market Forecast -2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Perennial Allergic Rhinitis - Market Insight, Epidemiology and Market Forecast -2032" report has been added to ResearchAndMarkets.com's offering.
  • The Perennial Allergic Rhinitis market report provides current treatment practices, emerging drugs, Perennial Allergic Rhinitis market share of the individual therapies, current and forecasted Perennial Allergic Rhinitis market Size from 2019 to 2032 segmented by seven major markets.
  • The Perennial Allergic Rhinitis market report gives a thorough understanding of the Perennial Allergic Rhinitis by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.
  • The Perennial Allergic Rhinitis epidemiology division provide insights about historical and current Perennial Allergic Rhinitis patient pool and forecasted trend for every seven major countries.

Hikma launches RYALTRIS™ seasonal allergic rhinitis nasal spray in the US

Retrieved on: 
Dienstag, August 30, 2022
Measles, Dow Jones, Treatment, Biologic, OTC, National Institute, Generic, Social media, Nose, MENA, Recurrence, Asthma, Virus, Social, Skin, Infection, Multimedia, Thought, SAR, Ethics in pharmaceutical sales, Breast milk, Immune system, Allergic rhinitis, Allergy, Fungus, DJSI, BSE, Risk, Tuberculosis, Dermatology, Taste, Health, Bacteria, Pregnancy, Patient, Pharmaceutical industry, Petroleum jelly, Birth control, Wood drying

LONDON and MAHWAH, N.J.and MUMBAI, India, Aug. 30, 2022 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical company, and Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd. (Glenmark), an innovation driven global pharmaceutical company, announced the launch of RYALTRIS™ (olopatadine hydrochloride and mometasone furoate nasal spray) in the US. RYALTRIS™ is approved by the US Food and Drug Administration (FDA) for the treatment of symptoms of seasonal allergic rhinitis (SAR) in  adult and pediatric patients 12 years of age and older. This launch builds upon Hikma's leading position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US.

Key Points: 
  • For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them.
  • We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world.
  • Ryaltris should not be used by anyone who has had an allergic reaction to olopatadine or mometasone.
  • Ryaltris should be used under close medical supervision in anyone who has had nose bleeds or nasal perforation.

Survey Finds Immunotherapy Use for Most Common Allergies Linked to Higher Number of Allergens, Related Comorbidities

Retrieved on: 
Montag, August 22, 2022
Inflammation, Sinusitis, HCP, Fatigue, Food, CEO, Immunotherapy, HCPS, Allergy, American Academy, Swelling, IV, Dizziness, Dust, LaTeX, Itch, Food allergy, Anxiety, Asthma, Multimedia, Pollen, Immunology, Animal, Allergic rhinitis, Atrium Health Union, Atopic dermatitis, Polyp (medicine), Industry, Cough, Wheeze, Vaccine, Dairy product, Public relations, Risk management

PHILADELPHIA, Aug. 22, 2022 /PRNewswire/ -- Immunotherapy use among people living with allergies is more prominent for those living with numerous allergy types and comorbidities, but is also linked to higher satisfaction with healthcare professionals and more active leveraging of condition management resources, according to a recent survey conducted by Health Union, the leader in social health. The inaugural Allergies In America survey illuminates the perspectives and experiences of people living with allergies.

Key Points: 
  • The inaugural Allergies In America survey illuminates the perspectives and experiences of people living with allergies.
  • Immunotherapy is an increasingly used form of long-term treatment for people living with allergies.
  • Of survey respondents living with respiratory allergies, 56% have currently or previously used immunotherapy.
  • Similarly, 85% of food allergy respondents who have used immunotherapy are living with at least five allergies, compared to half of those who have never used immunotherapy.

Insights on the Mucosal Atomization Devices Global Market to 2027 - Featuring Kurve Technology, Cook Medical, Medica Holdings and Integra LifeSciences Among Others - ResearchAndMarkets.com

Retrieved on: 
Donnerstag, August 18, 2022
Health, Biotechnology, DHE, NDA, Impeller, Technology, Trachea, Prevalence, Research, UDS, Patient, Allergic rhinitis, POD, US Foods, Food, Pharmaceutical industry

When the trigger is activated, it releases the piston and creates a jet stream of medicant through the nasal, buccal, and trachea.

Key Points: 
  • When the trigger is activated, it releases the piston and creates a jet stream of medicant through the nasal, buccal, and trachea.
  • Several key players in the market are focusing on developing novel gas-propelled devices for the easy and safe administration of drugs.
  • Thus, owing to the aforementioned factors, the application of gas-propelled mucosal atomization devices is expected to grow significantly during the forecast period.
  • In this region, the US holds the maximum share due to supportive healthcare policies, a high number of patients, and a developed healthcare market.

Protect Crawl Spaces from Mold with Americover's New Pro Crawl™ Anti-Mold Vapor Barrier

Retrieved on: 
Donnerstag, August 11, 2022
Asthma, Water damage, Growth, Humidity, Allergic rhinitis, Acute bronchitis, Friends, MPT, Solution, ASTM, Longevity, Health, Lumber

ESCONDIDO, Calif., Aug. 11, 2022 /PRNewswire-PRWeb/ -- Americover Inc. has launched its newest product, Pro Crawl™ Anti-Mold Vapor Barrier embedded with Mold Prevention Technology™ (MPT™). This product is the second generation of high-performance vapor barriers that began with the Original Pro Crawl™ Barrier designed to significantly reduce vapor transmission in the crawl space.

Key Points: 
  • ESCONDIDO, Calif., Aug. 11, 2022 /PRNewswire-PRWeb/ -- Americover Inc. has launched its newest product, Pro Crawl Anti-Mold Vapor Barrier embedded with Mold Prevention Technology (MPT) .
  • This product is the second generation of high-performance vapor barriers that began with the Original Pro Crawl Barrier designed to significantly reduce vapor transmission in the crawl space.
  • "We created the 10 mil Pro Crawl Anti-Mold Vapor Barrier with MPT to provide a peace of mind."
  • Americover's Pro Crawl Anti-Mold Vapor Barrier passes ASTM G21 mold resistance standards to prevent the growth & spread of toxic mold & mildew.

United BioPharma's Study Reveals New Class of Monoclonal Antibody for Effective Relief of Urticaria Symptoms

Retrieved on: 
Freitag, August 5, 2022
Antibody, CD23, Immunoglobulin E, Observation, Asthma, CSU, High-density lipoprotein, Prevalence, Research, Journal of Clinical Investigation, Chungnam National University, Patient, Quality of life, UBP, Atopic dermatitis, Allergic rhinitis, UAS7, JCI, Allergy, Ligelizumab, Food allergy, Neutralizing antibody, Hives, Immune system, Vaccine, Pharmaceutical industry, Omalizumab

TAIPEI, Aug. 5, 2022 /PRNewswire/ -- United BioPharma (UBP) today announced their latest results featuring unprecedented and unique functional characteristics of UB-221 monoclonal antibody in the phase I single-dose clinical trial, with chronic spontaneous urticaria (CSU) patients, to exhibit durable disease symptom relief. The results were published in the latest Journal of Clinical Investigation (JCI).  

Key Points: 
  • The chronic spontaneous urticaria (CSU) has known to be caused by a type of protein or antibodies produced by the immune system, known as Immunoglobulin E (IgE).
  • In the study, UB-221 has proven to be a potent IgE neutralizer and a significant inhibitor of IgE neo-synthesis.
  • The study also suggests this new class of monoclonal antibody shows promise for the prevention of the development of allergic symptoms, through targeting both high-affinity IgE receptor (FcRI) and low affinity IgE receptor (CD23) pathways.
  • In addition, a notable observation of the study is that UB-221 in free form can interact unrestricted with CD23.